Alder BioPharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 02 2017 - 8:00AM
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage
biopharmaceutical company developing monoclonal antibody
therapeutics, today announced that it will webcast its presentation
at the upcoming 35th Annual J.P. Morgan Healthcare Conference at
4:00 p.m. PT (7:00 p.m. ET) on Monday, January 9, 2017 in San
Francisco, CA. The presentation will feature a corporate overview
and update by Randall C. Schatzman, Ph.D., president and chief
executive officer.
A live audio webcast of the event can be accessed on the Events
& Presentations page of the Investors section of Alder's
website at http://www.alderbio.com, or by following the link below
in your web browser. An archived replay of the webcast will be
available on Alder's website for 30 days after the live event
concludes.
Link:
http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22492
About Alder BioPharmaceuticals,
Inc.Alder BioPharmaceuticals, Inc., is a clinical-stage
biopharmaceutical company that discovers, develops and seeks to
commercialize genetically engineered therapeutic antibodies with
the potential to meaningfully transform current treatment
paradigms. Alder's lead pivotal-stage product candidate,
eptinezumab, is being evaluated for migraine prevention.
Eptinezumab is a monoclonal antibody that inhibits calcitonin
gene-related peptide (CGRP), a protein that is active in mediating
the initiation of migraine. Alder is additionally evaluating
ALD1910, a preclinical product candidate also in development as a
migraine prevention therapy. ALD1910 is a monoclonal antibody that
inhibits pituitary adenylate cyclase-activating polypeptide-38
(PACAP-38), another protein that is active in mediating the
initiation of migraine. Clazakizumab, Alder's third program, is a
monoclonal antibody candidate that inhibits interleukin-6 and is
licensed to Vitaeris, Inc. For more information, please visit
http://www.alderbio.com.
Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
(212) 845-4271
(212) 845-4235
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals
(425) 408-8032
ir@alderbio.com
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Sep 2023 to Sep 2024